Answers are grounded in this paper and cite their sources.
The phosphoinositide 3-kinase (PI3K) signaling pathway has emerged as a well-established therapeutic target in oncology, driving substantial efforts toward the rational development of small-molecule inhibitors. Over the last 20 years, diverse structural categories of PI3K inhibitors have been engineered through structure-based design and medicinal chemistry refinement, encompassing pan-PI3K inhibitors, isoform-selective agents, and dual PI3K/mTOR inhibitors. Notably, several compounds including idelalisib, alpelisib, and copanlisib have gained regulatory approval, demonstrating the clinical significance of targeting specific PI3K isoforms in particular cancer settings. However, despite these achievements, the clinical application of first-generation inhibitors has been constrained by off-target toxicities, limited therapeutic windows, and unfavorable pharmacokinetic profiles. These limitations have spurred continued investigation into next-generation inhibitors featuring enhanced selectivity, diminished toxicity, and improved drug-like properties. This review summarizes recent progress in PI3K inhibitor development from 2021 to the present, which will guide the further development of next-generation therapeutic agents.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: